We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-11.4%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$57.4B
AUM Growth
-$7.29B
Cap. Flow
+$861M
Cap. Flow %
1.5%
Top 10 Hldgs %
21.3%
Holding
3,843
New
205
Increased
1,398
Reduced
1,819
Closed
309

Sector Composition

Rank Sector Weight
1 Technology 9.78%
2 Financials 8.85%
3 Healthcare 8.68%
4 Industrials 6.29%
5 Consumer Discretionary 5.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TRQ
3251
DELISTED
Turquoise Hill Resources Ltd
TRQ
$121K ﹤0.01%
+7,352
New +$132K
ENX
3252
DELISTED
Eaton Vance New York Municipal Bond Fund
ENX
$119K ﹤0.01%
+10,853
New +$119K
SMC
3253
Summit Midstream
SMC
$443M
$119K ﹤0.01%
788
-471
-37% -$98.2K
SOGO
3254
DELISTED
Sogou Inc. American Depositary Shares, each representing one Class A Ordinary Share
SOGO
$119K ﹤0.01%
22,700
-8,500
-27% -$51.7K
CB icon
3255
CALL
Chubb
CB
$134B
$118K ﹤0.01%
94,900
+6,500
+7% +$840K
CZZ
3256
DELISTED
Cosan Limited
CZZ
$118K ﹤0.01%
+13,388
New +$108K
MUS
3257
DELISTED
BLACKROCK MUNIHOLDINGS QUALITY FUND, INC.
MUS
$118K ﹤0.01%
10,463
-1,270
-11% -$14.4K
ADT icon
3258
ADT
ADT
$5.49B
$117K ﹤0.01%
19,538
-15,900
-45% -$120K
GGT
3259
Gabelli Multimedia Trust
GGT
$175M
$117K ﹤0.01%
16,891
-138
-0.8% -$1.12K
YCBD icon
3260
cbdMD
YCBD
$5.94M
$116K ﹤0.01%
+104
New +$148K
MFD
3261
DELISTED
Macquarie/First Trust Global Infrastructure/Utilities Dividend & Income Fund
MFD
$116K ﹤0.01%
12,572
-687
-5% -$7.08K
GFI icon
3262
Gold Fields
GFI
$35.7B
$114K ﹤0.01%
32,277
-1,500
-4% -$4.42K
ACHN
3263
DELISTED
Achillion Pharmaceuticals
ACHN
$114K ﹤0.01%
71,450
+7,400
+12% +$20.9K
GSM icon
3264
FerroAtlántica
GSM
$873M
$113K ﹤0.01%
71,041
-185,112
-72% -$886K
CHS
3265
DELISTED
Chicos FAS, Inc.
CHS
$113K ﹤0.01%
20,134
-405
-2% -$2.82K
QUOT
3266
DELISTED
Quotient Technology Inc
QUOT
$113K ﹤0.01%
10,540
-428
-4% -$5.37K
DMK
3267
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$112K ﹤0.01%
709
+256
+57% +$49.1K
AQ
3268
DELISTED
Aquantia Corp. Common Stock
AQ
$112K ﹤0.01%
+12,800
New +$130K
NCV
3269
Virtus Convertible & Income Fund
NCV
$392M
$111K ﹤0.01%
5,339
-1,825
-25% -$45.1K
NVAX icon
3270
Novavax
NVAX
$1.32B
$111K ﹤0.01%
3,019
WNEB icon
3271
Western New England Bancorp
WNEB
$278M
$111K ﹤0.01%
11,038
-6,017
-35% -$59.7K
PRTY
3272
DELISTED
Party City Holdco Inc.
PRTY
$111K ﹤0.01%
11,162
-23,940
-68% -$260K
MSI icon
3273
CALL
Motorola Solutions
MSI
$77.3B
$109K ﹤0.01%
117,400
-4,600
-4% -$571K
SWCH
3274
DELISTED
Switch, Inc. Class A Common Stock
SWCH
$108K ﹤0.01%
+15,438
New +$129K
TBBK icon
3275
The Bancorp
TBBK
$2.85B
$107K ﹤0.01%
13,385
-1,126
-8% -$10.6K

Similar funds

Raymond James & Associates's Q4 2018 Portfolio in Review

As of Q4 2018, Raymond James & Associates held 3,843 positions worth $57.4B, down 11% from $64.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Raymond James & Associates's Q4 2018 filing shows 205 new, 1,398 increased, 1,819 reduced and 309 closed positions. Its largest new stake was Linde: 549,404 shares worth $87.1M. The largest sale was Oracle, an estimated $124M.

By sector, the portfolio is most concentrated in Technology at 9.8% of assets, down from 11% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q4 2018 buy was Linde: 549,404 shares worth $87.1M.
  • Raymond James & Associates added most to State Street SPDR S&P 500 ETF Trust in Q4 2018, an estimated $368M increase.
  • Raymond James & Associates's biggest Q4 2018 reduction was Oracle, cutting an estimated $124M.
  • Raymond James & Associates fully exited Praxair Inc in Q4 2018, selling an estimated $110M.
  • Raymond James & Associates's ten largest holdings make up 21% of its $57.4B portfolio in Q4 2018.
  • Raymond James & Associates opened 205 new positions and closed 309 in Q4 2018.
  • Raymond James & Associates's portfolio value fell 11% quarter-over-quarter to $57.4B.

Based on Raymond James & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.